Welcome to our dedicated page for Outset Medical SEC filings (Ticker: OM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Outset Medical, Inc.'s SEC filings document operating results, product and service revenue, gross margin, cash resources, and guidance for its dialysis technology business. Recent Form 8-K reports furnish earnings releases for the Tablo Hemodialysis System business and disclose material events such as FDA 510(k) clearance for the next-generation Tablo platform.
Proxy materials and current reports also cover governance and compensation matters, including board composition, director independence, committee appointments, executive compensation tables, pay-versus-performance disclosures, and equity awards. The filing record ties these disclosures to Outset’s capital structure, Nasdaq-listed common stock, and medical-device regulatory environment.
Outset Medical, Inc. reported that its General Counsel, John L. Brottem, sold 224 shares of common stock on 01/07/2026 at a price of $4.27 per share. After this transaction, he beneficially owned 46,271 shares directly.
The filing explains that the sale was a required "sell to cover" transaction to satisfy tax withholding obligations tied to 447 shares of common stock underlying performance stock units that had been earned and vested, and it did not represent a discretionary trade by Brottem.
Outset Medical, Inc. Chair and CEO Leslie Trigg reported a small sale of company stock that was made only to cover taxes. On January 7, 2026, she sold 1,795 shares of common stock at $4.27 per share in a transaction coded “S,” described as a “sell to cover” for tax withholding related to previously earned PSUs. According to the disclosure, this sale was required to satisfy tax obligations and “does not represent a discretionary trade.”
Following the sale, Trigg beneficially owned 119,617 shares of common stock directly, plus 41,666 shares held indirectly through the Trigg 2002 Rev Trust and 584 shares held indirectly through the Trigg Family Trust.
OM filed a Rule 144 notice for a small planned stock sale. The filing covers the proposed sale of 108 shares of the issuer’s common stock through Morgan Stanley Smith Barney LLC on or about 01/07/2026, with the shares listed for trading on NASDAQ. The aggregate market value of this planned sale is reported as $461.16, based on market prices at the time of the notice.
The seller acquired the stock on 01/06/2026 through settlement of 289 vested performance stock units from the issuer as equity compensation for services rendered. Over the prior three months, the same seller disposed of 247 common shares on 11/17/2025 for gross proceeds of $1,136.20. By signing the notice, the seller represents that they are not aware of undisclosed material adverse information about OM’s current or prospective operations.
OM insider Leslie Trigg filed a notice of proposed sale of common stock under Rule 144. The filing covers the planned sale of 1,795 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $7,664.65 and 18,153,090 shares of common stock shown as outstanding.
The shares to be sold are part of a larger 4,904-share grant of common stock acquired on 01/06/2026 via settlement of vested performance stock units as equity compensation for services rendered. The filing also notes that Trigg previously sold 916 shares of common stock on 11/17/2025 for gross proceeds of $4,213.60. By signing, the seller represents they are not aware of undisclosed material adverse information about OM.
OM insider John Brottem filed a Rule 144 notice to sell 224 shares of common stock through Morgan Stanley Smith Barney LLC on approximately 01/07/2026, with an aggregate market value of $956.48 on the NASDAQ exchange. The filing notes that 18,153,090 shares of common stock were outstanding.
The shares to be sold come from 447 common shares acquired on 01/06/2026 via settlement of vested performance stock units as equity compensation for services rendered. The notice also reports that Brottem previously sold 388 shares of common stock on 11/17/2025 for gross proceeds of $1,784.80, and includes a representation that he is not aware of undisclosed material adverse information about OM.
Outset Medical, Inc. (OM) reported an insider transaction by its Chair and CEO, Leslie Trigg. On 11/17/2025, Trigg sold 916 shares of common stock at $4.60 per share in a transaction coded “S.” The company notes this was a required sale to cover tax withholding tied to the vesting of 1,770 shares of common stock underlying restricted stock units granted on January 6, 2023 and January 12, 2024, and it did not represent a discretionary trade. After the transaction, Trigg beneficially owned 121,412 shares directly and additional shares indirectly through the Trigg 2002 Rev Trust and the Trigg Family Trust.
Outset Medical, Inc. (OM) reported an insider share sale by its EVP Operations R&D & Service, Marc Nash. On 11/17/2025, Nash sold 247 shares of common stock at $4.60 per share in a transaction coded "S," leaving him with 48,268 shares beneficially owned. The company explains that the shares were sold solely to cover tax withholding obligations tied to the vesting of 674 shares of common stock underlying RSUs granted on March 15, 2023, July 24, 2023, and January 12, 2024, and that the sale did not represent a discretionary trade by Nash.
Outset Medical, Inc. reported an insider transaction by its General Counsel, John L. Brottem. On 11/17/2025, he sold 388 shares of common stock at $4.6 per share. The sale was required to cover tax withholding obligations tied to the vesting of 748 shares of common stock underlying restricted stock units granted on January 6, 2023 and January 12, 2024, and is described as a non-discretionary "sell to cover" transaction. After this trade, he directly holds 46,495 shares of Outset Medical common stock.
Outset Medical (OM) reported Q3 2025 results showing modest top-line growth and narrower losses. Revenue was $29.4 million, up slightly from $28.7 million a year ago, with product revenue of $20.6 million and service and other revenue of $8.9 million. Gross profit rose to $11.6 million as operating expenses declined, reducing the operating loss to $15.8 million. Net loss was $17.8 million, or $1.00 per share.
For the first nine months of 2025, revenue reached $90.6 million versus $84.2 million in 2024, and net loss improved to $62.2 million from $102.3 million. Cash, cash equivalents, restricted cash and short‑term investments totaled $182.0 million as of September 30, 2025. The company executed a 15‑for‑1 reverse stock split in March 2025 and completed financing steps earlier in the year, including issuing Series A convertible preferred stock that largely converted into 14,046,000 common shares at $12.00 per share and entering a $125 million term loan facility (with $100 million funded). As of November 6, 2025, shares outstanding were 18,153,090.
Outset Medical (OM) furnished an 8-K stating it issued a press release and will hold its earnings call to announce financial results for the quarter ended September 30, 2025, along with revised 2025 revenue guidance.
The company notes the information is furnished under Item 2.02 and not deemed filed. The report includes forward‑looking statements and points readers to SEC filings for risk factors. Exhibit 99.1 contains the press release titled “Outset Medical Reports Third-Quarter Results.”